SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
SOPHiA GENETICS (Nasdaq: SOPH) has expanded its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN) in a multi-year collaboration focused on breast cancer treatment optimization. The partnership will utilize SOPHiA GENETICS's multimodal AI Factories to analyze genomics, imaging, and clinical data to generate evidence on therapy efficacy and develop AI-powered predictive models.
The collaboration aims to generate real-world evidence in Europe and North America, leveraging one of healthcare's most diverse multimodal datasets to enhance clinical decision-making and treatment outcomes. The partnership highlights SOPHiA GENETICS's capabilities in managing complex healthcare data environments through secure, compliant, and scalable real-world AI applications.
SOPHiA GENETICS (Nasdaq: SOPH) ha ampliato la sua collaborazione con AstraZeneca (LSE/STO/Nasdaq: AZN) in un progetto pluriennale volto all'ottimizzazione del trattamento del cancro al seno. La partnership sfrutter脿 le AI Factories multimodali di SOPHiA GENETICS per analizzare dati genomici, di imaging e clinici, al fine di produrre evidenze sull'efficacia delle terapie e sviluppare modelli predittivi basati sull'intelligenza artificiale.
La collaborazione punta a generare evidenze reali in Europa e Nord America, utilizzando uno dei dataset multimodali pi霉 diversificati nel settore sanitario per migliorare le decisioni cliniche e i risultati terapeutici. Questa partnership sottolinea le capacit脿 di SOPHiA GENETICS nella gestione di ambienti dati sanitari complessi tramite applicazioni AI real-world sicure, conformi e scalabili.
SOPHiA GENETICS (Nasdaq: SOPH) ha ampliado su colaboraci贸n con AstraZeneca (LSE/STO/Nasdaq: AZN) en un acuerdo plurianual centrado en la optimizaci贸n del tratamiento del c谩ncer de mama. La asociaci贸n utilizar谩 las F谩bricas de IA multimodales de SOPHiA GENETICS para analizar datos gen贸micos, de imagen y cl铆nicos, con el objetivo de generar evidencia sobre la eficacia de las terapias y desarrollar modelos predictivos impulsados por IA.
La colaboraci贸n busca generar evidencia del mundo real en Europa y Norteam茅rica, aprovechando uno de los conjuntos de datos multimodales m谩s diversos en el 谩mbito sanitario para mejorar la toma de decisiones cl铆nicas y los resultados del tratamiento. La asociaci贸n destaca la capacidad de SOPHiA GENETICS para gestionar entornos de datos sanitarios complejos mediante aplicaciones de IA del mundo real seguras, conformes y escalables.
SOPHiA GENETICS (雮橃姢雼�: SOPH)电� AstraZeneca (LSE/STO/雮橃姢雼�: AZN)鞕� 鞙犽癌鞎� 旃橂 斓滌爜頇旊ゼ 鞙勴暅 雼る厔臧� 順戨牓鞚� 頇曤寑頄堨姷雼堧嫟. 鞚� 韺岉姼雱堨嫮鞚� SOPHiA GENETICS鞚� 雼れ 氇嫭 AI 韺╉啝毽�毳� 頇滌毄頃橃棳 鞙犾爠觳错暀, 鞓侅儊 氚� 鞛勳儊 雿办澊韯半ゼ 攵勳劃頃橁碃 旃橂 須臣鞐� 雽�頃� 歃濌卑毳� 靸濎劚頃橂┌ AI 旮半皹 鞓堨浮 氇嵏鞚� 臧滊皽頃� 鞓堨爼鞛呺媹雼�.
鞚措矆 順戨牓鞚� 鞙犽熃瓿� 攵侂鞐愳劀 鞁れ牅 雿办澊韯半ゼ 頇滌毄頃� 歃濌卑毳� 靸濎劚頃樀鐢 瓴冹潉 氇╉憸搿� 頃橂┌, 鞚橂 攵勳暭鞐愳劀 臧�鞛� 雼れ枒頃� 雼れ 氇嫭 雿办澊韯办厠 欷� 頃橂倶毳� 頇滌毄頃� 鞛勳儊 鞚橃偓瓴办爼瓿� 旃橂 瓴瓣臣毳� 頄レ儊鞁滍偆瓿犾瀽 頃╇媹雼�. 鞚� 韺岉姼雱堨嫮鞚� 氤奠灐頃� 鞚橂 雿办澊韯� 頇橁步鞚� 鞎堨爠頃橁碃 攴滌爼鞚� 欷�靾橅晿氅� 頇曥灔 臧�電ロ暅 鞁れ牅 AI 鞎犿攲毽紑鞚挫厴鞙茧 甏�毽晿电� SOPHiA GENETICS鞚� 鞐焿鞚� 臧曥“頃╇媹雼�.
SOPHiA GENETICS (Nasdaq : SOPH) a 茅tendu son partenariat avec AstraZeneca (LSE/STO/Nasdaq : AZN) dans le cadre d'une collaboration pluriannuelle ax茅e sur l'optimisation du traitement du cancer du sein. Ce partenariat utilisera les usines d'IA multimodales de SOPHiA GENETICS pour analyser les donn茅es g茅nomiques, d'imagerie et cliniques afin de g茅n茅rer des preuves sur l'efficacit茅 des th茅rapies et de d茅velopper des mod猫les pr茅dictifs bas茅s sur l'IA.
Cette collaboration vise 脿 produire des preuves issues du monde r茅el en Europe et en Am茅rique du Nord, en exploitant l'un des ensembles de donn茅es multimodales les plus diversifi茅s dans le domaine de la sant茅 pour am茅liorer la prise de d茅cision clinique et les r茅sultats des traitements. Ce partenariat met en lumi猫re les capacit茅s de SOPHiA GENETICS 脿 g茅rer des environnements de donn茅es de sant茅 complexes gr芒ce 脿 des applications d'IA r茅elles s茅curis茅es, conformes et 茅volutives.
SOPHiA GENETICS (Nasdaq: SOPH) hat seine Partnerschaft mit AstraZeneca (LSE/STO/Nasdaq: AZN) in einer mehrj盲hrigen Zusammenarbeit zur Optimierung der Brustkrebsbehandlung ausgeweitet. Die Partnerschaft wird die multimodalen KI-Fabriken von SOPHiA GENETICS nutzen, um Genomik-, Bildgebungs- und klinische Daten zu analysieren, um Evidenz zur Wirksamkeit von Therapien zu generieren und KI-gest眉tzte Vorhersagemodelle zu entwickeln.
Die Zusammenarbeit zielt darauf ab, in Europa und Nordamerika AG真人官方-World-Evidenz zu generieren und dabei einen der vielf盲ltigsten multimodalen Datens盲tze im Gesundheitswesen zu nutzen, um klinische Entscheidungen und Behandlungsergebnisse zu verbessern. Die Partnerschaft unterstreicht die F盲higkeiten von SOPHiA GENETICS, komplexe Gesundheitsdatenumgebungen durch sichere, konforme und skalierbare AG真人官方-World-KI-Anwendungen zu managen.
- Strategic expansion of partnership with major pharmaceutical company AstraZeneca
- Access to diverse multimodal healthcare datasets for AI model development
- Geographic expansion across Europe and North America for real-world evidence generation
- Reinforcement of SOPHiA GENETICS's position as a trusted AI technology partner in healthcare
- None.
Insights
SOPHiA GENETICS expands its commercial reach through a multi-year AI collaboration with AstraZeneca, strengthening its market position in precision oncology.
This expanded collaboration between SOPHiA GENETICS and AstraZeneca represents a significant commercial validation of SOPHiA's AI platform capabilities in the oncology space. The multi-year partnership will leverage SOPHiA's multimodal AI Factories to analyze complex datasets spanning genomics, imaging, and clinical information specifically for breast cancer applications.
The strategic value here is twofold: First, SOPHiA gains a stable revenue stream through this extended engagement with a pharmaceutical giant. Second, the collaboration enhances SOPHiA's competitive positioning in the growing AI-driven precision medicine market, which is projected to see substantial growth as healthcare increasingly embraces artificial intelligence for clinical decision support.
What makes this partnership particularly valuable is its focus on real-world evidence generation across Europe and North America. This approach addresses a critical industry need for data that reflects actual clinical practice outside controlled trial environments. By helping AstraZeneca understand treatment efficacy drivers in breast cancer through federated analytics (analyzing data where it resides without moving sensitive patient information), SOPHiA strengthens its position as a trusted intermediary in the healthcare AI ecosystem.
The development of a potential bespoke predictive model for breast cancer treatment optimization could also lead to proprietary clinical decision support tools with commercial applications beyond this single partnership, potentially creating additional revenue opportunities in the future.
Derived from cutting-edge computing protocols and trained on one of the most diverse multimodal datasets in healthcare, SOPHiA GENETICS's AI Factories offer powerful predictive insights for assessing patient prognosis and treatment response. AstraZeneca will utilize SOPHiA GENETICS's AI Factories to analyze multimodal healthcare data 鈥� including genomics, imaging, and clinical data 鈥� and generate AI-powered insights to help optimize breast cancer outcomes. The companies will also collaborate on real-world evidence generation in
"We are proud to deepen our partnership with AstraZeneca through this significant new initiative, which highlights the growing demand for secure, compliant, and scalable real-world AI applications," said Ross Muken, President of SOPHiA GENETICS. "Our platform is purpose-built to manage complex healthcare data environments, and this collaboration reinforces our shared commitment to driving better patient outcomes through trusted, federated analytics powered by data and AI."
"At AstraZeneca, a core component of our AI strategy has been rooted in the deployment of frontier AI solutions across oncology clinical development," said Jorge Reis-Filho, Chief AI and Data Scientist, AstraZeneca. "Fine tuning and augmenting our models with multimodal data 鈥� including our own data and the data that will be generated as part of this collaboration 鈥� is helping us to generate a more holistic understanding of disease biology and biomarkers to tailor the most effective treatment to patients living with cancer."
This collaboration reinforces SOPHiA GENETICS' position as a trusted technology partner and underlines its commitment to advancing global health through federated data analytics and artificial intelligence.
For more information on SOPHiA GENETICS, visit听, or connect on听.听
About SOPHiA GENETICS 听
SOPHiA GENETICS (Nasdaq: SOPH) is a听cloud-native healthcare technology听company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients听with cancer and rare disorders听across the globe. It is the creator of the SOPHiA DDM鈩� Platform, which听analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit听 and connect with us on听.听
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.听
SOPHiA GENETICS Forward-Looking Statements:听听
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the
View original content to download multimedia:
SOURCE SOPHiA GENETICS
FAQ
What is the purpose of SOPHiA GENETICS's expanded collaboration with AstraZeneca?
How will SOPHiA GENETICS's AI Factories benefit breast cancer treatment?
What types of data will be analyzed in the SOPH and AstraZeneca collaboration?
Where will SOPHiA GENETICS and AstraZeneca conduct their real-world evidence generation?
What makes SOPHiA GENETICS's AI Factories unique in healthcare?
